RESUMO
We report the frequency of lacrimal passage disorder and the outcomes of treatment. This retrospective study was performed on 55 cases that were treated with S-1 for at least 1 month. We asked patients about ocular symptoms. An ophthalmic surgeon examined all patients and diagnosed lacrimal passage disorder in 6 of 55 patients (12. 5%). The mean dose of S- 1 was 10, 300 mg, and the average period to onset of lacrimal passage disorder was 5. 7 months. The causes of epiphora included occlusion/stenosis of lacrimal canaliculus, occlusion of lacrimal puncta and stenosis of nasolacrimal duct. Lacrimal surgery was performed in all 6 patients and epiphora improved. Lacrimal passage disorder may result from systemic treatment of patients with S-1. Symptoms of lacrimal passage disorder improved with early detection and treatment by insertion of a silicone tube.
Assuntos
Doenças do Aparelho Lacrimal/induzido quimicamente , Ácido Oxônico/efeitos adversos , Tegafur/efeitos adversos , Idoso , Combinação de Medicamentos , Feminino , Humanos , Doenças do Aparelho Lacrimal/cirurgia , Masculino , Pessoa de Meia-Idade , Neoplasias/tratamento farmacológico , Ácido Oxônico/uso terapêutico , Tegafur/uso terapêuticoRESUMO
A 68-year-old male was referred to our hospital for treatment of left hemopneumothorax. Chest X-ray film and chest computed tomography scans showed emphysematous bulla at the apical portion of the left lung, pleural effusion and atelectasis of the lingular segment and lower lobe of the left lung. He underwent bullectomy and decortication. On the 9 post operative days, the patient was discharged without complication. Pathological diagnosis was lung adenocarcinoma originated from bulla wall. We must recognize that cystic lung disease is a high risk factor of the lung cancer.
